Updated findings from the phase 3 RUBY trial suggest durable disease control for dostarlimab (Jemperli) combined with carboplatin and paclitaxel in dMMR/MSI-H primary advanced or recurrent endometrial cancer. At a median follow-up of 55.6 months, the trial’s 4-year progression-free survival reached 57.9% with dostarlimab versus 15.7% with chemotherapy alone. Mixture cure modeling estimated that 54% of patients may have curative potential with the combination, alongside an improved overall survival trend (HR 0.69; median 44.6 vs 28.2 months).